[PDF][PDF] Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer.
…, A Norman, JK Joffe, M Hughes, J Mansi… - Journal of Clinical …, 1997 - Citeseer
Purpose: We report the results of a prospectively ran-domized study that compared the
combination of epirubicin, cisplatin, and protracted venous infusion fluorouracil (5-FU)(ECF …
combination of epirubicin, cisplatin, and protracted venous infusion fluorouracil (5-FU)(ECF …
Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo …
…, B Ejlertsen, SKL Chia, J Mansi… - The Lancet …, 2016 - thelancet.com
Background Neratinib, an irreversible tyrosine-kinase inhibitor of HER1, HER2, and HER4,
has clinical activity in patients with HER2-positive metastatic breast cancer. We aimed to …
has clinical activity in patients with HER2-positive metastatic breast cancer. We aimed to …
Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled …
…, H Iwata, G von Minckwitz, SKL Chia, J Mansi… - The lancet …, 2017 - thelancet.com
Background ExteNET showed that 1 year of neratinib, an irreversible pan-HER tyrosine
kinase inhibitor, significantly improves 2-year invasive disease-free survival after trastuzumab-…
kinase inhibitor, significantly improves 2-year invasive disease-free survival after trastuzumab-…
Randomized phase IIB trial of BLP25 liposome vaccine in stage IIIB and IV non–small-cell lung cancer
…, A Price, R Sawhney, M Davis, J Mansi… - Journal of Clinical …, 2005 - ascopubs.org
Purpose To evaluate the effect of BLP25 liposome vaccine (L-BLP25) on survival and
toxicity in patients with stage IIIB and IV non–small-cell lung cancer (NSCLC). Secondary …
toxicity in patients with stage IIIB and IV non–small-cell lung cancer (NSCLC). Secondary …
Duration of chemotherapy in advanced non–small-cell lung cancer: A randomized trial of three versus six courses of mitomycin, vinblastine, and cisplatin
…, DC Talbot, MC Nicolson, JL Mansi… - Journal of clinical …, 2001 - ascopubs.org
PURPOSE: So far there are no published data on optimal duration of chemotherapy for
advanced non–small-cell lung cancer (NSCLC); six or more courses are usually recommended. …
advanced non–small-cell lung cancer (NSCLC); six or more courses are usually recommended. …
Plasma 25-hydroxy vitamin D concentrations, vitamin D receptor genotype and breast cancer risk in a UK Caucasian population
LC Lowe, M Guy, JL Mansi, C Peckitt, J Bliss… - European journal of …, 2005 - Elsevier
Low levels of 25-hydroxy vitamin D (25(OH)D) and polymorphisms in the vitamin D receptor
gene (VDR) have been found separately to increase risk of breast cancer. The aim of this …
gene (VDR) have been found separately to increase risk of breast cancer. The aim of this …
Outcome of primary-breast-cancer patients with micrometastases: a long-term follow-up study
JL Mansi, H Gogas, JM Biss, JC Gazet, U Berger… - The Lancet, 1999 - thelancet.com
Background Bone-marrow micrometastases have been found in patients with primary breast
cancer. We report long-term follow-up of women with primary breast cancer, diagnosed …
cancer. We report long-term follow-up of women with primary breast cancer, diagnosed …
[HTML][HTML] 6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised …
…, K Raynes, HB Higgins, M Wilcox, C Plummer, J Mansi… - The Lancet, 2019 - thelancet.com
Background Adjuvant trastuzumab significantly improves outcomes for patients with HER2-positive
early breast cancer. The standard treatment duration is 12 months but shorter …
early breast cancer. The standard treatment duration is 12 months but shorter …
[PDF][PDF] Phase III randomized trial of doxorubicin and docetaxel versus doxorubicin and cyclophosphamide as primary medical therapy in women with breast cancer: an …
…, M Highley, RCF Leonard, JL Mansi - Journal of Clinical …, 2005 - academia.edu
Purpose To compare the clinical and pathologic response rates of doxorubicin and
cyclophosphamide (AC) with doxorubicin and docetaxel (AD) as primary chemotherapy in …
cyclophosphamide (AC) with doxorubicin and docetaxel (AD) as primary chemotherapy in …
Autocrine metabolism of vitamin D in normal and malignant breast tissue
…, CM Banwell, M Guy, KW Colston, JL Mansi… - Clinical Cancer …, 2005 - AACR
Purpose: Vitamin D seems to exert a protective effect against common cancers, although this
does not correlate with circulating levels of active 1,25-dihydroxyvitamin D 3 [1,25(OH) 2 D …
does not correlate with circulating levels of active 1,25-dihydroxyvitamin D 3 [1,25(OH) 2 D …